Source link : https://www.newshealth.biz/health-news/sonelokimab-yields-significant-improvements-in-active-psa/
TOPLINE: Treatment of patients with active psoriatic arthritis with sonelokimab — an interleukin (IL)-17A- and IL-17F-inhibiting nanobody — led to a higher percentage of patients with 50% or greater improvement in American College of Rheumatology response criteria (ACR50) compared with the placebo in a phase 2 trial. METHODOLOGY: Sonelokimab is a 40-kDa nanobody that binds […]
Author : News Health
Publish date : 2024-06-26 05:12:22
Copyright for syndicated content belongs to the linked Source.
Categories